Multiple APOBEC3 restriction factors for HIV-1 and one vif to rule them all

Journal of Molecular Biology

Volumn 426, Issue 6, 2014, Pages 1220-1245

  Desimmie, Belete A ^a   Delviks Frankenberrry, Krista A ^a   Burdick, Ryan C ^a   Qi, Dongfei ^a   Izumi, Taisuke ^a   Pathak, Vinay K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

APOBEC3F; APOBEC3G; APOBEC3H; restriction factor; Vif

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3A; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3B; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3C; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3H; CYTIDINE; CYTIDINE DEAMINASE; HEAT SHOCK PROTEIN 70; HYDROLASE; INTERFERON; MESSENGER RNA; NEDD8 PROTEIN; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; DEAMINATION; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVERSE TRANSCRIPTION; REVIEW; SITE DIRECTED MUTAGENESIS; VIRION; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

APOBEC3F; APOBEC3G; APOBEC3H; RESTRICTION FACTOR; VIF;

CYTOSINE DEAMINASE; DNA, VIRAL; HIV; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 84896692562     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2013.10.033     Document Type: Review

References (277)

1. H.C. Smith, R.P. Bennett, A. Kizilyer, W.M. McDougall, and K.M. Prohaska Functions and regulation of the APOBEC family of proteins Semin Cell Dev Biol 23 2012 258 268
2. B. Teng, C.F. Burant, and N.O. Davidson Molecular cloning of an apolipoprotein B messenger RNA editing protein Science 260 1993 1816 1819
3. N. Navaratnam, J.R. Morrison, S. Bhattacharya, D. Patel, T. Funahashi, and F. Giannoni et al. The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase J Biol Chem 268 1993 20709 20712
4. M. Muramatsu, K. Kinoshita, S. Fagarasan, S. Yamada, Y. Shinkai, and T. Honjo Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme Cell 102 2000 553 563
5. A. Vonica, A. Rosa, B.L. Arduini, and A.H. Brivanlou APOBEC2, a selective inhibitor of TGFbeta signaling, regulates left-right axis specification during early embryogenesis Dev Biol 350 2011 13 23
6. C. Etard, U. Roostalu, and U. Strahle Lack of Apobec2-related proteins causes a dystrophic muscle phenotype in zebrafish embryos J Cell Biol 189 2010 527 539
7. Y. Sato, H.C. Probst, R. Tatsumi, Y. Ikeuchi, M.S. Neuberger, and C. Rada Deficiency in APOBEC2 leads to a shift in muscle fiber type, diminished body mass, and myopathy J Biol Chem 285 2010 7111 7118
8. W. Liao, S.H. Hong, B.H. Chan, F.B. Rudolph, S.C. Clark, and L. Chan APOBEC-2, a cardiac- and skeletal muscle-specific member of the cytidine deaminase supergene family Biochem Biophys Res Commun 260 1999 398 404
9. M.C. Mikl, I.N. Watt, M. Lu, W. Reik, S.L. Davies, and M.S. Neuberger et al. Mice deficient in APOBEC2 and APOBEC3 Mol Cell Biol 25 2005 7270 7277
10. I.B. Rogozin, M.K. Basu, I.K. Jordan, Y.I. Pavlov, and E.V. Koonin APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis Cell Cycle 4 2005 1281 1285
11. A.M. Sheehy, N.C. Gaddis, J.D. Choi, and M.H. Malim Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein Nature 418 2002 646 650
12. D. Lecossier, F. Bouchonnet, F. Clavel, and A.J. Hance Hypermutation of HIV-1 DNA in the absence of the Vif protein Science 300 2003 1112
13. R.S. Harris, A.M. Sheehy, H.M. Craig, M.H. Malim, and M.S. Neuberger DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses Nat Immunol 4 2003 641 643
14. S.G. Conticello, R.S. Harris, and M.S. Neuberger The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G Curr Biol 13 2003 2009 2013
15. M. Kobayashi, A. Takaori-Kondo, Y. Miyauchi, K. Iwai, and T. Uchiyama Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function J Biol Chem 280 2005 18573 18578
16. M. Marin, K.M. Rose, S.L. Kozak, and D. Kabat HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation Nat Med 9 2003 1398 1403
17. A. Mehle, B. Strack, P. Ancuta, C. Zhang, M. McPike, and D. Gabuzda Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway J Biol Chem 279 2004 7792 7798
18. A.M. Sheehy, N.C. Gaddis, and M.H. Malim The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif Nat Med 9 2003 1404 1407
19. K. Stopak, C. de Noronha, W. Yonemoto, and W.C. Greene HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability Mol Cell 12 2003 591 601
20. X. Yu, Y. Yu, B. Liu, K. Luo, W. Kong, and P. Mao et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex Science 302 2003 1056 1060
21. R.S. Harris, J.F. Hultquist, and D.T. Evans The restriction factors of human immunodeficiency virus J Biol Chem 287 2012 40875 40883
22. A. Jarmuz, A. Chester, J. Bayliss, J. Gisbourne, I. Dunham, and J. Scott et al. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22 Genomics 79 2002 285 296
23. F.A. Koning, E.N. Newman, E.Y. Kim, K.J. Kunstman, S.M. Wolinsky, and M.H. Malim Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets J Virol 83 2009 9474 9485
24. E.W. Refsland, M.D. Stenglein, K. Shindo, J.S. Albin, W.L. Brown, and R.S. Harris Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction Nucleic Acids Res 38 2010 4274 4284
25. T. Nitta, S. Lee, D. Ha, M. Arias, C.A. Kozak, and H. Fan Moloney murine leukemia virus glyco-gag facilitates xenotropic murine leukemia virus-related virus replication through human APOBEC3-independent mechanisms Retrovirology 9 2012 58
26. C.M. Okeoma, N. Lovsin, B.M. Peterlin, and S.R. Ross APOBEC3 inhibits mouse mammary tumour virus replication in vivo Nature 445 2007 927 930
27. B. Mussil, U. Sauermann, D. Motzkus, C. Stahl-Hennig, and S. Sopper Increased APOBEC3G and APOBEC3F expression is associated with low viral load and prolonged survival in simian immunodeficiency virus infected rhesus monkeys Retrovirology 8 2011 77
28. B. Mangeat, P. Turelli, G. Caron, M. Friedli, L. Perrin, and D. Trono Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts Nature 424 2003 99 103
29. A. Sasada, A. Takaori-Kondo, K. Shirakawa, M. Kobayashi, A. Abudu, and M. Hishizawa et al. APOBEC3G targets human T-cell leukemia virus type 1 Retrovirology 2 2005 32
30. R. Mahieux, R. Suspene, F. Delebecque, M. Henry, O. Schwartz, and S. Wain-Hobson et al. Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases J Gen Virol 86 2005 2489 2494
31. J. Fan, G. Ma, K. Nosaka, J. Tanabe, Y. Satou, and A. Koito et al. APOBEC3G generates nonsense mutations in human T-cell leukemia virus type 1 proviral genomes in vivo J Virol 84 2010 7278 7287
32. H.L. Wiegand, and B.R. Cullen Inhibition of alpharetrovirus replication by a range of human APOBEC3 proteins J Virol 81 2007 13694 13699
33. M. Lochelt, F. Romen, P. Bastone, H. Muckenfuss, N. Kirchner, and Y.B. Kim et al. The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein Proc Natl Acad Sci USA 102 2005 7982 7987
34. F. Delebecque, R. Suspene, S. Calattini, N. Casartelli, A. Saib, and A. Froment et al. Restriction of foamy viruses by APOBEC cytidine deaminases J Virol 80 2006 605 614
35. R.A. Russell, H.L. Wiegand, M.D. Moore, A. Schafer, M.O. McClure, and B.R. Cullen Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors J Virol 79 2005 8724 8731
36. J.F. Arias, T. Koyama, M. Kinomoto, and K. Tokunaga Retroelements versus APOBEC3 family members: no great escape from the magnificent seven Front Microbiol 3 2012 275
37. P. Turelli, B. Mangeat, S. Jost, S. Vianin, and D. Trono Inhibition of hepatitis B virus replication by APOBEC3G Science 303 2004 1829
38. J.P. Vartanian, D. Guetard, M. Henry, and S. Wain-Hobson Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions Science 320 2008 230 233
39. K.M. Chen, E. Harjes, P.J. Gross, A. Fahmy, Y. Lu, and K. Shindo et al. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G Nature 452 2008 116 119
40. L.G. Holden, C. Prochnow, Y.P. Chang, R. Bransteitter, L. Chelico, and U. Sen et al. Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications Nature 456 2008 121 124
41. S. Kitamura, H. Ode, and Y. Iwatani Structural features of antiviral APOBEC3 proteins are linked to their functional activities Front Microbiol 2 2011 258
42. C. Prochnow, R. Bransteitter, M.G. Klein, M.F. Goodman, and X.S. Chen The APOBEC-2 crystal structure and functional implications for the deaminase AID Nature 445 2007 447 451
43. I.J. Byeon, J. Ahn, M. Mitra, C.H. Byeon, K. Hercik, and J. Hritz et al. NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificity Nat Commun 4 2013 1890
44. S.M. Shandilya, M.N. Nalam, E.A. Nalivaika, P.J. Gross, J.C. Valesano, and K. Shindo et al. Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces Structure 18 2010 28 38
45. M.F. Bohn, S.M. Shandilya, J.S. Albin, T. Kouno, B.D. Anderson, and R.M. McDougle et al. Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain Structure 21 2013 1042 1050
46. E. Harjes, P.J. Gross, K.M. Chen, Y. Lu, K. Shindo, and R. Nowarski et al. An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model J Mol Biol 389 2009 819 832
47. T.C. Krzysiak, J. Jung, J. Thompson, D. Baker, and A.M. Gronenborn APOBEC2 is a monomer in solution: implications for APOBEC3G models Biochemistry 51 2012 2008 2017
48. A. Furukawa, T. Nagata, A. Matsugami, Y. Habu, R. Sugiyama, and F. Hayashi et al. Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G EMBO J 28 2009 440 451
49. S. Kitamura, H. Ode, M. Nakashima, M. Imahashi, Y. Naganawa, and T. Kurosawa et al. The APOBEC3C crystal structure and the interface for HIV-1 Vif binding Nat Struct Mol Biol 19 2012 1005 1010
50. F. Kiefer, K. Arnold, M. Kunzli, L. Bordoli, and T. Schwede The SWISS-MODEL repository and associated resources Nucleic Acids Res 37 2009 D387 D392
51. K. Arnold, L. Bordoli, J. Kopp, and T. Schwede The SWISS-MODEL workspace: a Web-based environment for protein structure homology modelling Bioinformatics 22 2006 195 201
52. J.L. Smith, and V.K. Pathak Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif J Virol 84 2010 12599 12608
53. J.S. Albin, R.S. LaRue, J.A. Weaver, W.L. Brown, K. Shindo, and E. Harjes et al. A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif J Biol Chem 285 2010 40785 40792
54. H. Huthoff, and M.H. Malim Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation J Virol 81 2007 3807 3815
55. R.A. Russell, J. Smith, R. Barr, D. Bhattacharyya, and V.K. Pathak Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif J Virol 83 2009 1992 2003
56. K. Xie, M.P. Sowden, G.S. Dance, A.T. Torelli, H.C. Smith, and J.E. Wedekind The structure of a yeast RNA-editing deaminase provides insight into the fold and function of activation-induced deaminase and APOBEC-1 Proc Natl Acad Sci USA 101 2004 8114 8119
57. R. Bransteitter, C. Prochnow, and X.S. Chen The current structural and functional understanding of APOBEC deaminases Cell Mol Life Sci 66 2009 3137 3147
58. G. Senavirathne, M. Jaszczur, P.A. Auerbach, T.G. Upton, L. Chelico, and M.F. Goodman et al. Single-stranded DNA scanning and deamination by APOBEC3G cytidine deaminase at single molecule resolution J Biol Chem 287 2012 15826 15835
59. H.C. Losey, A.J. Ruthenburg, and G.L. Verdine Crystal structure of Staphylococcus aureus tRNA adenosine deaminase TadA in complex with RNA Nat Struct Mol Biol 13 2006 153 159
60. L. Chelico, P. Pham, P. Calabrese, and M.F. Goodman APOBEC3G DNA deaminase acts processively 3′ → 5′ on single-stranded DNA Nat Struct Mol Biol 13 2006 392 399
61. R.M. Kohli, S.R. Abrams, K.S. Gajula, R.W. Maul, P.J. Gearhart, and J.T. Stivers A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase J Biol Chem 284 2009 22898 22904
62. S. Harjes, W.C. Solomon, M. Li, K.M. Chen, E. Harjes, and R.S. Harris et al. Impact of H216 on the DNA binding and catalytic activities of the HIV restriction factor APOBEC3G J Virol 87 2013 7008 7014
63. A. Rathore, M.A. Carpenter, O. Demir, T. Ikeda, M. Li, and N.M. Shaban et al. The local dinucleotide preference of APOBEC3G can be altered from 5′-CC to 5′-TC by a single amino acid substitution J Mol Biol 425 2013 4442 4454
64. M.A. Langlois, R.C. Beale, S.G. Conticello, and M.S. Neuberger Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities Nucleic Acids Res 33 2005 1913 1923
65. M. Wang, C. Rada, and M.S. Neuberger Altering the spectrum of immunoglobulin V gene somatic hypermutation by modifying the active site of AID J Exp Med 207 2010 141 153
66. L. Betts, S. Xiang, S.A. Short, R. Wolfenden, and C.W. Carter Cytidine deaminase. The 2.3 Å crystal structure of an enzyme: transition-state analog complex J Mol Biol 235 1994 635 656
67. L. Zhang, J. Saadatmand, X. Li, F. Guo, M. Niu, and J. Jiang et al. Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation Virology 370 2008 113 121
68. W. Zhang, G. Chen, A.M. Niewiadomska, R. Xu, and X.F. Yu Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins PLoS One 3 2008 e3963
69. R.A. Russell, and V.K. Pathak Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F J Virol 81 2007 8201 8210
70. K.L. Zhang, B. Mangeat, M. Ortiz, V. Zoete, D. Trono, and A. Telenti et al. Model structure of human APOBEC3G PLoS One 2 2007 e378
71. H. Xu, E.S. Svarovskaia, R. Barr, Y. Zhang, M.A. Khan, and K. Strebel et al. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion Proc Natl Acad Sci USA 101 2004 5652 5657
72. B. Schrofelbauer, D. Chen, and N.R. Landau A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif) Proc Natl Acad Sci USA 101 2004 3927 3932
73. B. Mangeat, P. Turelli, S. Liao, and D. Trono A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action J Biol Chem 279 2004 14481 14483
74. H.P. Bogerd, B.P. Doehle, H.L. Wiegand, and B.R. Cullen A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor Proc Natl Acad Sci USA 101 2004 3770 3774
75. Y. Dang, L.M. Siew, X. Wang, Y. Han, R. Lampen, and Y.H. Zheng Human cytidine deaminase APOBEC3H restricts HIV-1 replication J Biol Chem 283 2008 11606 11614
76. M.M. Li, L.I. Wu, and M. Emerman The range of human APOBEC3H sensitivity to lentiviral Vif proteins J Virol 84 2010 88 95
77. A. Zhen, T. Wang, K. Zhao, Y. Xiong, and X.F. Yu A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity J Virol 84 2010 1902 1911
78. S.R. Marcsisin, P.S. Narute, L.A. Emert-Sedlak, M. Kloczewiak, T.E. Smithgall, and J.R. Engen On the solution conformation and dynamics of the HIV-1 viral infectivity factor J Mol Biol 410 2011 1008 1022
79. J.R. Bergeron, H. Huthoff, D.A. Veselkov, R.L. Beavil, P.J. Simpson, and S.J. Matthews et al. The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex PLoS Pathog 6 2010 e1000925
80. K. Luo, Z. Xiao, E. Ehrlich, Y. Yu, B. Liu, and S. Zheng et al. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G Proc Natl Acad Sci USA 102 2005 11444 11449
81. A. Mehle, J. Goncalves, M. Santa-Marta, M. McPike, and D. Gabuzda Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation Genes Dev 18 2004 2861 2866
82. A. Mehle, E.R. Thomas, K.S. Rajendran, and D. Gabuzda A zinc-binding region in Vif binds Cul5 and determines cullin selection J Biol Chem 281 2006 17259 17265
83. Y. Yu, Z. Xiao, E.S. Ehrlich, X. Yu, and X.F. Yu Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines Genes Dev 18 2004 2867 2872
84. T. Yamashita, K. Kamada, K. Hatcho, A. Adachi, and M. Nomaguchi Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F Microbes Infect 10 2008 1142 1149
85. B. Schrofelbauer, T. Senger, G. Manning, and N.R. Landau Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G J Virol 80 2006 5984 5991
86. M. Ooms, M. Letko, M. Binka, and V. Simon The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif PLoS One 8 2013 e57744
87. Z. He, W. Zhang, G. Chen, R. Xu, and X.F. Yu Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction J Mol Biol 381 2008 1000 1011
88. E. Pery, K.S. Rajendran, A.J. Brazier, and D. Gabuzda Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif J Virol 83 2009 2374 2381
89. M. Santa-Marta, F.A. da Silva, A.M. Fonseca, and J. Goncalves HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation J Biol Chem 280 2005 8765 8775
90. C. Tian, X. Yu, W. Zhang, T. Wang, R. Xu, and X.F. Yu Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F J Virol 80 2006 3112 3115
91. V. Simon, V. Zennou, D. Murray, Y. Huang, D.D. Ho, and P.D. Bieniasz Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification PLoS Pathog 1 2005 e6
92. G. Chen, Z. He, T. Wang, R. Xu, and X.F. Yu A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G J Virol 83 2009 8674 8682
93. Y. Dang, X. Wang, T. Zhou, I.A. York, and Y.H. Zheng Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization J Virol 83 2009 8544 8552
94. Y. Dang, R.W. Davis, I.A. York, and Y.H. Zheng Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity J Virol 84 2010 5741 5750
95. H. Xu, E. Chertova, J. Chen, D.E. Ott, J.D. Roser, and W.S. Hu et al. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions Virology 360 2007 247 256
96. E.S. Svarovskaia, H. Xu, J.L. Mbisa, R. Barr, R.J. Gorelick, and A. Ono et al. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs J Biol Chem 279 2004 35822 35828
97. B.P. Doehle, A. Schafer, H.L. Wiegand, H.P. Bogerd, and B.R. Cullen Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion J Virol 79 2005 8201 8207
98. K. Luo, B. Liu, Z. Xiao, Y. Yu, X. Yu, and R. Gorelick et al. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging J Virol 78 2004 11841 11852
99. V. Zennou, D. Perez-Caballero, H. Gottlinger, and P.D. Bieniasz APOBEC3G incorporation into human immunodeficiency virus type 1 particles J Virol 78 2004 12058 12061
100. M.A. Khan, S. Kao, E. Miyagi, H. Takeuchi, R. Goila-Gaur, and S. Opi et al. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes J Virol 79 2005 5870 5874
101. T.M. Alce, and W. Popik APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein J Biol Chem 279 2004 34083 34086
102. A. Schafer, H.P. Bogerd, and B.R. Cullen Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor Virology 328 2004 163 168
103. Y. Bulliard, P. Turelli, U.F. Rohrig, V. Zoete, B. Mangeat, and O. Michielin et al. Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition J Virol 83 2009 12611 12621
104. K. Belanger, M. Savoie, M.C. Rosales Gerpe, J.F. Couture, and M.A. Langlois Binding of RNA by APOBEC3G controls deamination-independent restriction of retroviruses Nucleic Acids Res 41 2013 7438 7452
105. F. Navarro, B. Bollman, H. Chen, R. Konig, Q. Yu, and K. Chiles et al. Complementary function of the two catalytic domains of APOBEC3G Virology 333 2005 374 386
106. Y. Iwatani, H. Takeuchi, K. Strebel, and J.G. Levin Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect J Virol 80 2006 5992 6002
107. Y.L. Chiu, V.B. Soros, J.F. Kreisberg, K. Stopak, W. Yonemoto, and W.C. Greene Cellular APOBEC3G restricts HIV-1 infection in resting CD4 + T cells Nature 435 2005 108 114
108. Y.L. Chiu, H.E. Witkowska, S.C. Hall, M. Santiago, V.B. Soros, and C. Esnault et al. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition Proc Natl Acad Sci USA 103 2006 15588 15593
109. T. Wang, C. Tian, W. Zhang, P.T. Sarkis, and X.F. Yu Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging J Mol Biol 375 2008 1098 1112
110. T. Wang, C. Tian, W. Zhang, K. Luo, P.T. Sarkis, and L. Yu et al. 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G J Virol 81 2007 13112 13124
111. D. Bach, S. Peddi, B. Mangeat, A. Lakkaraju, K. Strub, and D. Trono Characterization of APOBEC3G binding to 7SL RNA Retrovirology 5 2008 54
112. T. Izumi, R. Burdick, M. Shigemi, S. Plisov, W.-S. Hu, and V.K. Pathak Mov10 and APOBEC3G localization to processing bodies is not required for virion incorporation and antiviral activity J Virol 87 2013 11047 11062
113. S. Jager, D.Y. Kim, J.F. Hultquist, K. Shindo, R.S. LaRue, and E. Kwon et al. Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection Nature 481 2012 371 375
114. W. Zhang, J. Du, S.L. Evans, Y. Yu, and X.F. Yu T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction Nature 481 2012 376 379
115. G. Mercenne, S. Bernacchi, D. Richer, G. Bec, S. Henriet, and J.C. Paillart et al. HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation Nucleic Acids Res 38 2010 633 646
116. S. Kao, M.A. Khan, E. Miyagi, R. Plishka, A. Buckler-White, and K. Strebel The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity J Virol 77 2003 11398 11407
117. Y. Feng, R.P. Love, and L. Chelico HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G J Biol Chem 288 2013 6083 6094
118. K.M. Cheney, and Á. McKnight Interferon-alpha mediates restriction of human immunodeficiency virus type-1 replication in primary human macrophages at an early stage of replication PLoS One 5 2010 e13521
119. V. Cobos Jimenez, T. Booiman, S.W. de Taeye, K.A. van Dort, M.A. Rits, and J. Hamann et al. Differential expression of HIV-1 interfering factors in monocyte-derived macrophages stimulated with polarizing cytokines or interferons Sci Rep 2 2012 763
120. V. Mohanram, A.E. Skold, S.M. Bachle, S.K. Pathak, and A.L. Spetz IFN-alpha induces APOBEC3G, F, and A in immature dendritic cells and limits HIV-1 spread to CD4 + T cells J Immunol 190 2013 3346 3353
121. H. Chen, L.W. Wang, Y.Q. Huang, and Z.J. Gong Interferon-alpha induces high expression of APOBEC3G and STAT-1 in vitro and in vivo Int J Mol Sci 11 2010 3501 3512
122. M.A. Farrow, E.-Y. Kim, S.M. Wolinsky, and A.M. Sheehy NFAT and IRF proteins regulate transcription of the anti-HIV gene, APOBEC3G J Biol Chem 286 2011 2567 2577
123. W. Hou, X. Wang, L. Ye, L. Zhou, Z.Q. Yang, and E. Riedel et al. Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages J Virol 83 2009 3834 3842
124. R. Sugiyama, H. Nishitsuji, A. Furukawa, M. Katahira, Y. Habu, and H. Takeuchi et al. Heat shock protein 70 inhibits HIV-1 Vif-mediated ubiquitination and degradation of APOBEC3G J Biol Chem 286 2011 10051 10057
125. R. Sugiyama, M. Abe, H. Nishitsuji, Y. Murakami, H. Takeuchi, and H. Takaku Induction of heat-shock protein 70 by prostaglandin A inhibits HIV-1 Vif-mediated degradation of APOBEC3G Antiviral Res 99 2013 307 311
126. D.J. Stanley, K. Bartholomeeusen, D.C. Crosby, D.Y. Kim, E. Kwon, and L. Yen et al. Inhibition of a NEDD8 cascade restores restriction of HIV by APOBEC3G PLoS Pathog 8 2012 e1003085
127. J. Tan, X. Wang, K. Devadas, J. Zhao, P. Zhang, and I. Hewlett Some mechanisms of FLIP expression in inhibition of HIV-1 replication in Jurkat cells, CD4 + T cells and PBMCs J Cell Physiol 228 2013 2305 2313
128. R.M. Oguariri, L. Dai, J.W. Adelsberger, A. Rupert, R. Stevens, and J. Yang et al. Interleukin-2 inhibits HIV-1 replication in some human T cell lymphotrophic virus-1-infected cell lines via the induction and incorporation of APOBEC3G into the virion J Biol Chem 288 2013 17812 17822
129. K.S. Stopak, Y.L. Chiu, J. Kropp, R.M. Grant, and W.C. Greene Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells J Biol Chem 282 2007 3539 3546
130. K. Shirakawa, A. Takaori-Kondo, M. Yokoyama, T. Izumi, M. Matsui, and K. Io et al. Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif Nat Struct Mol Biol 15 2008 1184 1191
131. A.G. Lada, I.S. Waisertreiger, C.E. Grabow, A. Prakash, G.E. Borgstahl, and I.B. Rogozin et al. Replication protein A (RPA) hampers the processive action of APOBEC3G cytosine deaminase on single-stranded DNA PLoS One 6 2011 e24848
132. Y. Zhou, X. Wang, M. Liu, Q. Hu, L. Song, and L. Ye et al. A critical function of toll-like receptor-3 in the induction of anti-human immunodeficiency virus activities in macrophages Immunology 131 2010 40 49
133. K.M. Rose, M. Marin, S.L. Kozak, and D. Kabat Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus J Biol Chem 279 2004 41744 41749
134. H. Muckenfuss, J.K. Kaiser, E. Krebil, M. Battenberg, C. Schwer, and K. Cichutek et al. Sp1 and Sp3 regulate basal transcription of the human APOBEC3G gene Nucleic Acids Res 35 2007 3784 3796
135. K.L. McFarland, J.M. Klingenberg, S.T. Boyce, and D.M. Supp Expression of genes encoding antimicrobial proteins and members of the toll-like receptor/nuclear factor-kappaB pathways in engineered human skin Wound Repair Regen 16 2008 534 541
136. Y. Komohara, S. Suekane, M. Noguchi, K. Matsuoka, A. Yamada, and K. Itoh Expression of APOBEC3G in kidney cells Tissue Antigens 69 2007 95 98
137. Y.J. Wang, X. Wang, H. Zhang, L. Zhou, S. Liu, and D.L. Kolson et al. Expression and regulation of antiviral protein APOBEC3G in human neuronal cells J Neuroimmunol 206 2009 14 21
138. K. Watashi, M. Khan, V.R. Yedavalli, M.L. Yeung, K. Strebel, and K.T. Jeang Human immunodeficiency virus type 1 replication and regulation of APOBEC3G by peptidyl prolyl isomerase Pin1 J Virol 82 2008 9928 9936
139. S.M. Kinoshita, and S. Taguchi NF-IL6 (C/EBPbeta) induces HIV-1 replication by inhibiting cytidine deaminase APOBEC3G Proc Natl Acad Sci USA 105 2008 15022 15027
140. Y. Ogawa, T. Kawamura, T. Kimura, M. Ito, A. Blauvelt, and S. Shimada Gram-positive bacteria enhance HIV-1 susceptibility in Langerhans cells, but not in dendritic cells, via Toll-like receptor activation Blood 113 2009 5157 5166
141. W.F. Wong, K. Kohu, T. Chiba, T. Sato, and M. Satake Interplay of transcription factors in T-cell differentiation and function: the role of Runx Immunology 132 2011 157 164
142. J. Du, K. Zhao, Y. Rui, P. Li, X. Zhou, and W. Zhang et al. Differential requirements for HIV-1 Vif-mediated APOBEC3G degradation and RUNX1-mediated transcription by core binding factor beta J Virol 87 2013 1906 1911
143. J.F. Hultquist, R.M. McDougle, B.D. Anderson, and R.S. Harris HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor beta on genetically distinct surfaces AIDS Res Hum Retroviruses 28 2012 1543 1551
144. D.Y. Kim, E. Kwon, P.D. Hartley, D.C. Crosby, S. Mann, and N.J. Krogan et al. CBFbeta stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression Mol Cell 49 2013 632 644
145. J.D. Salter, G.M. Lippa, I.A. Belashov, and J.E. Wedekind Core-binding factor beta increases the affinity between human Cullin 5 and HIV-1 Vif within an E3 ligase complex Biochemistry 51 2012 8702 8704
146. X. Zhou, S.L. Evans, X. Han, Y. Liu, and X.-F. Yu Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase components PLoS One 7 2012 e33495
147. T. Hori, F. Osaka, T. Chiba, C. Miyamoto, K. Okabayashi, and N. Shimbara et al. Covalent modification of all members of human cullin family proteins by NEDD8 Oncogene 18 1999 6829 6834
148. M.D. Petroski, and R.J. Deshaies Function and regulation of cullin-RING ubiquitin ligases Nat Rev Mol Cell Biol 6 2005 9 20
149. T.A. Soucy, P.G. Smith, M.A. Milhollen, A.J. Berger, J.M. Gavin, and S. Adhikari et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer Nature 458 2009 732 736
150. V. Pitini, C. Arrigo, and G. Altavilla How cells respond to interferons J Clin Oncol 28 2010 e439
151. P.R.A. Meylan, J.C. Guatelli, J.R. Munis, D.D. Richman, and R.S. Kornbluth Mechanisms for the inhibition of HIV replication by interferons-α, -β, and -γ, in primary human macrophages Virology 193 1993 138 148
152. C. Goujon, and M.H. Malim Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells J Virol 84 2010 9254 9266
153. T.M.L. Souza, D.Q. Rodrigues, C.P.B. Passaes, V. Barreto-de-Souza, R.S. Aguiar, and J.R. Temerozo et al. The nerve growth factor reduces APOBEC3G synthesis and enhances HIV-1 transcription and replication in human primary macrophages Blood 117 2011 2944 2952
154. H. Ankel, S. Mittnacht, and H. Jacobsen Antiviral activity of prostaglandin A on encephalomyocarditis virus-infected cells: a unique effect unrelated to interferon J Gen Virol 66 1985 2355 2364
155. A. Rossi, G. Elia, and M.G. Santoro Inhibition of nuclear factor κB by prostaglandin A1: an effect associated with heat shock transcription factor activation Proc Natl Acad Sci USA 94 1997 746 750
156. M.M. Hayes, B.R. Lane, S.R. King, D.M. Markovitz, and M.J. Coffey Peroxisome proliferator-activated receptor gamma agonists inhibit HIV-1 replication in macrophages by transcriptional and post-transcriptional effects J Biol Chem 277 2002 16913 16919
157. U. Basu, J. Chaudhuri, C. Alpert, S. Dutt, S. Ranganath, and G. Li et al. The AID antibody diversification enzyme is regulated by protein kinase A phosphorylation Nature 438 2005 508 511
158. L. Pasqualucci, Y. Kitaura, H. Gu, and R. Dalla-Favera PKA-mediated phosphorylation regulates the function of activation-induced deaminase (AID) in B cells Proc Natl Acad Sci USA 103 2006 395 400
159. Z.L. Demorest, M. Li, and R.S. Harris Phosphorylation directly regulates the intrinsic DNA cytidine deaminase activity of activation-induced deaminase and APOBEC3G protein J Biol Chem 286 2011 26568 26575
160. F. Kopietz, A.A. Jaguva Vasudevan, M. Kramer, H. Muckenfuss, R. Sanzenbacher, and K. Cichutek et al. Interaction of human immunodeficiency virus type 1 Vif with APOBEC3G is not dependent on serine/threonine phosphorylation status J Gen Virol 93 2012 2425 2430
161. K. Gillick, D. Pollpeter, P. Phalora, E.Y. Kim, S.M. Wolinsky, and M.H. Malim Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination J Virol 87 2013 1508 1517
162. K.N. Bishop, R.K. Holmes, A.M. Sheehy, N.O. Davidson, S.J. Cho, and M.H. Malim Cytidine deamination of retroviral DNA by diverse APOBEC proteins Curr Biol 14 2004 1392 1396
163. V. Zennou, and P.D. Bieniasz Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates Virology 349 2006 31 40
164. C. Chaipan, J.L. Smith, W.S. Hu, and V.K. Pathak APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4 + T cells and macrophages J Virol 87 2013 444 453
165. J.F. Hultquist, J.A. Lengyel, E.W. Refsland, R.S. LaRue, L. Lackey, and W.L. Brown et al. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1 J Virol 85 2011 11220 11234
166. Y. Dang, X. Wang, W.J. Esselman, and Y.H. Zheng Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family J Virol 80 2006 10522 10533
167. X. Wang, A. Abudu, S. Son, Y. Dang, P.J. Venta, and Y.H. Zheng Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity J Virol 85 2011 3142 3152
168. B.P. Doehle, A. Schafer, and B.R. Cullen Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif Virology 339 2005 281 288
169. A. Harari, M. Ooms, L.C. Mulder, and V. Simon Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H J Virol 83 2009 295 303
170. R.S. Aguiar, N. Lovsin, A. Tanuri, and B.M. Peterlin Vpr.A3A chimera inhibits HIV replication J Biol Chem 283 2008 2518 2525
171. V.K. Pathak, and H.M. Temin Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations Proc Natl Acad Sci USA 87 1990 6019 6023
172. R. Suspene, P. Sommer, M. Henry, S. Ferris, D. Guetard, and S. Pochet et al. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase Nucleic Acids Res 32 2004 2421 2429
173. B. Berkhout, and A. de Ronde APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations AIDS 18 2004 1861 1863
174. H. Zhang, B. Yang, R.J. Pomerantz, C. Zhang, S.C. Arunachalam, and L. Gao The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA Nature 424 2003 94 98
175. R.S. Harris, K.N. Bishop, A.M. Sheehy, H.M. Craig, S.K. Petersen-Mahrt, and I.N. Watt et al. DNA deamination mediates innate immunity to retroviral infection Cell 113 2003 803 809
176. Q. Yu, R. Konig, S. Pillai, K. Chiles, M. Kearney, and S. Palmer et al. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome Nat Struct Mol Biol 11 2004 435 442
177. K. Shindo, A. Takaori-Kondo, M. Kobayashi, A. Abudu, K. Fukunaga, and T. Uchiyama The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity J Biol Chem 278 2003 44412 44416
178. Y. Yang, F. Guo, S. Cen, and L. Kleiman Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F Virology 365 2007 92 100
179. F. Guo, S. Cen, M. Niu, Y. Yang, R.J. Gorelick, and L. Kleiman The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA J Virol 81 2007 11322 11331
180. Y. Iwatani, D.S. Chan, F. Wang, K.S. Maynard, W. Sugiura, and A.M. Gronenborn et al. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G Nucleic Acids Res 35 2007 7096 7108
181. K.N. Bishop, M. Verma, E.Y. Kim, S.M. Wolinsky, and M.H. Malim APOBEC3G inhibits elongation of HIV-1 reverse transcripts PLoS Pathog 4 2008 e1000231
182. J.L. Anderson, and T.J. Hope APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells Virology 375 2008 1 12
183. X.Y. Li, F. Guo, L. Zhang, L. Kleiman, and S. Cen APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription J Biol Chem 282 2007 32065 32074
184. R.K. Holmes, F.A. Koning, K.N. Bishop, and M.H. Malim APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G J Biol Chem 282 2007 2587 2595
185. E.N. Newman, R.K. Holmes, H.M. Craig, K.C. Klein, J.R. Lingappa, and M.H. Malim et al. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity Curr Biol 15 2005 166 170
186. J.L. Mbisa, R. Barr, J.A. Thomas, N. Vandegraaff, I.J. Dorweiler, and E.S. Svarovskaia et al. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration J Virol 81 2007 7099 7110
187. K. Luo, T. Wang, B. Liu, C. Tian, Z. Xiao, and J. Kappes et al. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation J Virol 81 2007 7238 7248
188. F. Guo, S. Cen, M. Niu, J. Saadatmand, and L. Kleiman Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication J Virol 80 2006 11710 11722
189. J.L. Mbisa, W. Bu, and V.K. Pathak APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms J Virol 84 2010 5250 5259
190. K.N. Bishop, R.K. Holmes, A.M. Sheehy, and M.H. Malim APOBEC-mediated editing of viral RNA Science 305 2004 645
191. K.N. Bishop, R.K. Holmes, and M.H. Malim Antiviral potency of APOBEC proteins does not correlate with cytidine deamination J Virol 80 2006 8450 8458
192. G. Hache, M.T. Liddament, and R.S. Harris The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain J Biol Chem 280 2005 10920 10924
193. C.M. Holtz, H.A. Sadler, and L.M. Mansky APOBEC3G cytosine deamination hotspots are defined by both sequence context and single-stranded DNA secondary structure Nucleic Acids Res 41 2013 6139 6148
194. R.C. Beale, S.K. Petersen-Mahrt, I.N. Watt, R.S. Harris, C. Rada, and M.S. Neuberger Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo J Mol Biol 337 2004 585 596
195. M.T. Liddament, W.L. Brown, A.J. Schumacher, and R.S. Harris APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo Curr Biol 14 2004 1385 1391
196. H.L. Wiegand, B.P. Doehle, H.P. Bogerd, and B.R. Cullen A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins EMBO J 23 2004 2451 2458
197. H. Chen, C.E. Lilley, Q. Yu, D.V. Lee, J. Chou, and I. Narvaiza et al. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons Curr Biol 16 2006 480 485
198. S.K. Pillai, M. Abdel-Mohsen, J. Guatelli, M. Skasko, A. Monto, and K. Fujimoto et al. Role of retroviral restriction factors in the interferon-alpha-mediated suppression of HIV-1 in vivo Proc Natl Acad Sci USA 109 2012 3035 3040
199. J.P. Vartanian, M. Henry, and S. Wain-Hobson Sustained G → A hypermutation during reverse transcription of an entire human immunodeficiency virus type 1 strain Vau group O genome J Gen Virol 83 2002 801 805
200. A.E. Armitage, A. Katzourakis, T. de Oliveira, J.J. Welch, R. Belshaw, and K.N. Bishop et al. Conserved footprints of APOBEC3G on hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences J Virol 82 2008 8743 8761
201. J.E. Fitzgibbon, S. Mazar, and D.T. Dubin A new type of G → A hypermutation affecting human immunodeficiency virus AIDS Res Hum Retroviruses 9 1993 833 838
202. M. Janini, M. Rogers, D.R. Birx, and F.E. McCutchan Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells J Virol 75 2001 7973 7986
203. M. OhAinle, J.A. Kerns, H.S. Malik, and M. Emerman Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H J Virol 80 2006 3853 3862
204. R. Suspene, C. Rusniok, J.P. Vartanian, and S. Wain-Hobson Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication Nucleic Acids Res 34 2006 4677 4684
205. L. Chelico, C. Prochnow, D.A. Erie, X.S. Chen, and M.F. Goodman Structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G J Biol Chem 285 2010 16195 16205
206. O.G. Berg, R.B. Winter, and P.H. von Hippel Diffusion-driven mechanisms of protein translocation on nucleic acids. 1. Models and theory Biochemistry 20 1981 6929 6948
207. Y. Feng, and L. Chelico Intensity of deoxycytidine deamination of HIV-1 proviral DNA by the retroviral restriction factor APOBEC3G is mediated by the noncatalytic domain J Biol Chem 286 2011 11415 11426
208. L.S. Shlyakhtenko, A.Y. Lushnikov, A. Miyagi, M. Li, R.S. Harris, and Y.L. Lyubchenko Nanoscale structure and dynamics of ABOBEC3G complexes with single-stranded DNA Biochemistry 51 2012 6432 6440
209. R. Nowarski, E. Britan-Rosich, T. Shiloach, and M. Kotler Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase Nat Struct Mol Biol 15 2008 1059 1066
210. L. Chelico, P. Pham, and M.F. Goodman Mechanisms of APOBEC3G-catalyzed processive deamination of deoxycytidine on single-stranded DNA Nat Struct Mol Biol 16 2009 454 455
211. R. Nowarski, E. Britan-Rosich, and M. Kotler Reply to "Mechanisms of APOBEC3G-catalyzed processive deamination of deoxycytidine on single-stranded DNA" Nat Struct Mol Biol 16 2009 455 456
212. M.B. Adolph, J. Webb, and L. Chelico Retroviral restriction factor APOBEC3G delays the initiation of DNA synthesis by HIV-1 reverse transcriptase PLoS One 8 2013 e64196
213. G.J. Klarmann, X. Chen, T.W. North, and B.D. Preston Incorporation of uracil into minus strand DNA affects the specificity of plus strand synthesis initiation during lentiviral reverse transcription J Biol Chem 278 2003 7902 7909
214. S.M. Kaiser, and M. Emerman Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G J Virol 80 2006 875 882
215. M.A. Langlois, and M.S. Neuberger Human APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1 J Virol 82 2008 4660 4664
216. J.D. Salter, J. Krucinska, J. Raina, H.C. Smith, and J.E. Wedekind A hydrodynamic analysis of APOBEC3G reveals a monomer-dimer-tetramer self-association that has implications for anti-HIV function Biochemistry 48 2009 10685 10687
217. L.S. Shlyakhtenko, A.Y. Lushnikov, M. Li, L. Lackey, R.S. Harris, and Y.L. Lyubchenko Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G J Biol Chem 286 2011 3387 3395
218. J.E. Wedekind, R. Gillilan, A. Janda, J. Krucinska, J.D. Salter, and R.P. Bennett et al. Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits J Biol Chem 281 2006 38122 38126
219. H. Huthoff, F. Autore, S. Gallois-Montbrun, F. Fraternali, and M.H. Malim RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1 PLoS Pathog 5 2009 e1000330
220. L. Chelico, E.J. Sacho, D.A. Erie, and M.F. Goodman A model for oligomeric regulation of APOBEC3G cytosine deaminase-dependent restriction of HIV J Biol Chem 283 2008 13780 13791
221. Y.N. Friew, V. Boyko, W.S. Hu, and V.K. Pathak Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA Retrovirology 6 2009 56
222. W.M. McDougall, C. Okany, and H.C. Smith Deaminase activity on single-stranded DNA (ssDNA) occurs in vitro when APOBEC3G cytidine deaminase forms homotetramers and higher-order complexes J Biol Chem 286 2011 30655 30661
223. L.C. Mulder, M. Ooms, S. Majdak, J. Smedresman, C. Linscheid, and A. Harari et al. Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes J Virol 84 2010 9613 9617
224. E. Miyagi, C.R. Brown, S. Opi, M. Khan, R. Goila-Gaur, and S. Kao et al. Stably expressed APOBEC3F has negligible antiviral activity J Virol 84 2010 11067 11075
225. J.S. Albin, G. Hache, J.F. Hultquist, W.L. Brown, and R.S. Harris Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function J Virol 84 2010 10209 10219
226. E.W. Refsland, J.F. Hultquist, and R.S. Harris Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n PLoS Pathog 8 2012 e1002800
227. B.K. Berges, W.H. Wheat, B.E. Palmer, E. Connick, and R. Akkina HIV-1 infection and CD4 T cell depletion in the humanized Rag2 -/- gamma c -/- (RAG-hu) mouse model Retrovirology 3 2006 76
228. S. Gorantla, H. Sneller, L. Walters, J.G. Sharp, S.J. Pirruccello, and J.T. West et al. Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2 -/- gammac -/- mice J Virol 81 2007 2700 2712
229. Z. Sun, P.W. Denton, J.D. Estes, F.A. Othieno, B.L. Wei, and A.K. Wege et al. Intrarectal transmission, systemic infection, and CD4 + T cell depletion in humanized mice infected with HIV-1 J Exp Med 204 2007 705 714
230. S. Watanabe, K. Terashima, S. Ohta, S. Horibata, M. Yajima, and Y. Shiozawa et al. Hematopoietic stem cell-engrafted NOD/SCID/IL2Rgamma null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses Blood 109 2007 212 218
231. L. Zhang, G.I. Kovalev, and L. Su HIV-1 infection and pathogenesis in a novel humanized mouse model Blood 109 2007 2978 2981
232. D.S. An, B. Poon, R. Ho Tsong Fang, K. Weijer, B. Blom, and H. Spits et al. Use of a novel chimeric mouse model with a functionally active human immune system to study human immunodeficiency virus type 1 infection Clin Vaccine Immunol 14 2007 391 396
233. S. Baenziger, R. Tussiwand, E. Schlaepfer, L. Mazzucchelli, M. Heikenwalder, and M.O. Kurrer et al. Disseminated and sustained HIV infection in CD34 + cord blood cell-transplanted Rag2 -/- gamma c -/- mice Proc Natl Acad Sci USA 103 2006 15951 15956
234. W.L. Ince, L. Zhang, Q. Jiang, K. Arrildt, L. Su, and R. Swanstrom Evolution of the HIV-1 env gene in the Rag2 -/- gammaC -/- humanized mouse model J Virol 84 2010 2740 2752
235. K. Sato, T. Izumi, N. Misawa, T. Kobayashi, Y. Yamashita, and M. Ohmichi et al. Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice J Virol 84 2010 9546 9556
236. J.F. Krisko, F. Martinez-Torres, J.L. Foster, and J.V. Garcia HIV restriction by APOBEC3 in humanized mice PLoS Pathog 9 2013 e1003242
237. P. Lan, N. Tonomura, A. Shimizu, S. Wang, and Y.G. Yang Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34 + cell transplantation Blood 108 2006 487 492
238. M.W. Melkus, J.D. Estes, A. Padgett-Thomas, J. Gatlin, P.W. Denton, and F.A. Othieno et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1 Nat Med 12 2006 1316 1322
239. A. Rambaut, D. Posada, K.A. Crandall, and E.C. Holmes The causes and consequences of HIV evolution Nat Rev Genet 5 2004 52 61
240. H.A. Sadler, M.D. Stenglein, R.S. Harris, and L.M. Mansky APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis J Virol 84 2010 7396 7404
241. U. Neogi, A. Shet, P.N. Sahoo, I. Bontell, M.L. Ekstrand, and A.C. Banerjea et al. Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals J Int AIDS Soc 16 2013 18472
242. G. Hache, L.M. Mansky, and R.S. Harris Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance AIDS Rev 8 2006 148 157
243. P. Jern, R.A. Russell, V.K. Pathak, and J.M. Coffin Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance PLoS Pathog 5 2009 e1000367
244. K. Deforche, R. Camacho, K.V. Laethem, B. Shapiro, Y. Moreau, and A. Rambaut et al. Estimating the relative contribution of dNTP pool imbalance and APOBEC3G/3F editing to HIV evolution in vivo J Comput Biol 14 2007 1105 1114
245. D. Ebrahimi, F. Anwar, and M.P. Davenport APOBEC3 has not left an evolutionary footprint on the HIV-1 genome J Virol 85 2011 9139 9146
246. N. Wood, T. Bhattacharya, B.F. Keele, E. Giorgi, M. Liu, and B. Gaschen et al. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC PLoS Pathog 5 2009 e1000414
247. A.E. Armitage, K. Deforche, C.H. Chang, E. Wee, B. Kramer, and J.J. Welch et al. APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon PLoS Genet 8 2012 e1002550
248. L.M. Eyzaguirre, M. Charurat, R.R. Redfield, W.A. Blattner, J.K. Carr, and M.M. Sajadi Elevated hypermutation levels in HIV-1 natural viral suppressors Virology 443 2013 306 312
249. Y. Kourteva, M. De Pasquale, T. Allos, C. McMunn, and R.T. D'Aquila APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo Virology 430 2012 1 9
250. A.M. Land, T.B. Ball, M. Luo, R. Pilon, P. Sandstrom, and J.E. Embree et al. Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya J Virol 82 2008 8172 8182
251. N.K. Ulenga, A.D. Sarr, S. Thakore-Meloni, J.L. Sankale, G. Eisen, and P.J. Kanki Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F J Infect Dis 198 2008 486 492
252. M. Biasin, L. Piacentini, S. Lo Caputo, Y. Kanari, G. Magri, and D. Trabattoni et al. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals J Infect Dis 195 2007 960 964
253. X. Jin, A. Brooks, H. Chen, R. Bennett, R. Reichman, and H. Smith APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia J Virol 79 2005 11513 11516
254. J.A. Vazquez-Perez, C.E. Ormsby, R. Hernandez-Juan, K.J. Torres, and G. Reyes-Teran APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression Retrovirology 6 2009 23
255. S.K. Gandhi, J.D. Siliciano, J.R. Bailey, R.F. Siliciano, and J.N. Blankson Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors J Virol 82 2008 3125 3130
256. K. Mous, W. Jennes, M. Camara, M. Seydi, G. Daneau, and S. Mboup et al. Expression analysis of LEDGF/p75, APOBEC3G, TRIM5alpha, and tetherin in a Senegalese cohort of HIV-1-exposed seronegative individuals PLoS One 7 2012 e33934
257. K. Reddy, C.A. Winkler, L. Werner, K. Mlisana, S.S. Abdool Karim, and T. Ndung'u APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4 + T-cell counts and plasma viral load AIDS 24 2010 195 204
258. T. Bunupuradah, M. Imahashi, T. Iampornsin, K. Matsuoka, Y. Iwatani, and T. Puthanakit et al. Association of APOBEC3G genotypes and CD4 decline in Thai and Cambodian HIV-infected children with moderate immune deficiency AIDS Res Ther 9 2012 34
259. P. An, G. Bleiber, P. Duggal, G. Nelson, M. May, and B. Mangeat et al. APOBEC3G genetic variants and their influence on the progression to AIDS J Virol 78 2004 11070 11076
260. H.S. Valcke, N.F. Bernard, J. Bruneau, M. Alary, C.M. Tsoukas, and M. Roger APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians AIDS 20 2006 1984 1986
261. K.K. Singh, Y. Wang, K.P. Gray, M. Farhad, S. Brummel, and T. Fenton et al. Genetic variants in the host restriction factor APOBEC3G are associated with HIV-1-related disease progression and central nervous system impairment in children J Acquir Immune Defic Syndr 62 2013 197 203
262. M. Zhao, W. Geng, Y. Jiang, X. Han, H. Cui, and D. Dai et al. The associations of hA3G and hA3B mRNA levels with HIV disease progression among HIV-infected individuals of China J Acquir Immune Defic Syndr 53 2010 S4 S9
263. N.D. Amoedo, A.O. Afonso, S.M. Cunha, R.H. Oliveira, E.S. Machado, and M.A. Soares Expression of APOBEC3G/3F and G-to-A hypermutation levels in HIV-1-infected children with different profiles of disease progression PLoS One 6 2011 e24118
264. F.A. De Maio, C.A. Rocco, P.C. Aulicino, R. Bologna, A. Mangano, and L. Sen APOBEC3-mediated editing in HIV type 1 from pediatric patients and its association with APOBEC3G/CUL5 polymorphisms and Vif variability AIDS Res Hum Retroviruses 28 2012 619 627
265. T.L. Kieffer, P. Kwon, R.E. Nettles, Y. Han, S.C. Ray, and R.F. Siliciano G → A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4 + T cells in vivo J Virol 79 2005 1975 1980
266. R.A. Russell, M.D. Moore, W.S. Hu, and V.K. Pathak APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA Retrovirology 6 2009 16
267. C. Pace, J. Keller, D. Nolan, I. James, S. Gaudieri, and C. Moore et al. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation J Virol 80 2006 9259 9269
268. S.J. Cho, H. Drechsler, R.C. Burke, M.Q. Arens, W. Powderly, and N.O. Davidson APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4 + T-cell count J Virol 80 2006 2069 2072
269. H. Do, A. Vasilescu, G. Diop, T. Hirtzig, S.C. Heath, and C. Coulonges et al. Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort J Infect Dis 191 2005 159 163
270. A. Piantadosi, D. Humes, B. Chohan, R.S. McClelland, and J. Overbaugh Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif J Virol 83 2009 7805 7814
271. G.B. Jacobs, M. Nistal, A. Laten, E.J. van Rensburg, A. Rethwilm, and W. Preiser et al. Molecular analysis of HIV type 1 vif sequences from Cape Town, South Africa AIDS Res Hum Retroviruses 24 2008 991 994
272. J. Peng, Z. Ao, C. Matthews, X. Wang, S. Ramdahin, and X. Chen et al. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication J Mol Biol 425 2013 2840 2852
273. F.A. De Maio, C.A. Rocco, P.C. Aulicino, R. Bologna, A. Mangano, and L. Sen Effect of HIV-1 Vif variability on progression to pediatric AIDS and its association with APOBEC3G and CUL5 polymorphisms Infect Genet Evol 11 2011 1256 1262
274. S. Fourati, I. Malet, M. Binka, S. Boukobza, M. Wirden, and S. Sayon et al. Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals AIDS 24 2010 2313 2321
275. Y. Iwabu, M. Kinomoto, M. Tatsumi, H. Fujita, M. Shimura, and Y. Tanaka et al. Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes J Biol Chem 285 2010 35350 35358
276. I. Lisovsky, S.M. Schader, R.D. Sloan, M. Oliveira, D. Coutsinos, and N.F. Bernard et al. HIV-1 subtype variability in Vif derived from molecular clones affects APOBEC3G-mediated host restriction Intervirology 56 2013 258 264
277. Y. Dang, X. Wang, I.A. York, and Y.H. Zheng Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity J Virol 84 2010 8561 8570